Dogwood Therapeutics, Inc.

Stage 4 · Declining · week 2

As of Oct 22, 2026, Dogwood Therapeutics is in Stage 4, the downtrend phase, now in week 2 (since Oct 14, 2026). It closed at $1.12, 83.6% below its 52-week high and below its 200-day average, which is falling.

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. More about the company

$1.12

-2.86% today

$38.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is DWTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 26w

S4 36w

S4 30w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 1w → S3 9w → S4 26w → S1 4w → S4 36w → S1 2w → S2 8w → S3 8w → S4 2w → S3 1w → S2 4w → S3 1w → S4 6w → S1 8w → S2 6w → S3 4w → S4 30w → S1 8w → S4 1w current

Total tracked: 166 weeks across 19 stage runs.

DWTX among Biotechnology471st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…471	DWTXDogwood Therapeutics, Inc.	Stage 4 · wk 2	11	−25.8%

vs 52W High

-83.6%

$1.12 lo$6.82 hi

83.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-44.9%

200 DMA: $2.03 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.85x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-25.8%

-25.3%

-20.0%

YTD

-73.6%

-80.1%

Scan Membership

Breakout Watch

Latest: 2025-06-26

5 appearances in last 60 days. First seen: 2022-01-28.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 0.85x

2026-10-21S4

Wk 2 · Vol 0.49x

2026-10-20S4

Wk 1 · Vol 0.65x

2026-10-19S4

Wk 1 · Vol 3.18x

2026-10-16S4

Wk 1 · Vol 0.98x

2026-10-15S4

Wk 1 · Vol 1.45x

2026-10-14S41→4

Wk 1 · Vol 1.20x

2026-10-13S1

Wk 8 · Vol 1.59x

2026-10-12S1

Wk 8 · Vol 0.64x

2026-10-09S1

Wk 8 · Vol 0.98x

2026-10-08S1

Wk 8 · Vol 0.92x

2026-10-07S1

Wk 8 · Vol 0.75x

Moving averages & range

50 DMA

$1.80

200 DMA

$2.03

52W High

$6.82

52W Low

$1.12

5D Low

$1.12

Resistance levels (recent highs)

20d High

$1.52

60d High

$2.68

120d High

$2.68

250d High

$6.82

Next resistance

+35.7%

to 20d High

P/E (TTM)

0.5

Forward -0.2

ROE

-47.8%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.6

Dogwood Therapeutics: quick answers

What stage is Dogwood Therapeutics in?

As of Oct 22, 2026, Dogwood Therapeutics (DWTX) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 14, 2026 and is in week 2. What the four stages mean

Is Dogwood Therapeutics in an uptrend?

No. Dogwood Therapeutics is in a Stage 4 downtrend. It trades 44.9% below its 200-day average, which is falling.

How far is Dogwood Therapeutics from its 52-week high?

Dogwood Therapeutics closed at $1.12 on Oct 22, 2026, 83.6% below its 52-week high of $6.82. Its 52-week low is $1.12.

How has Dogwood Therapeutics performed over the past year?

As of Oct 22, 2026, Dogwood Therapeutics is down 80.1% over the past year and down 73.6% so far in 2026.

Which sector and industry is Dogwood Therapeutics in?

Dogwood Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.